Preclinical Evaluation of a Novel Adenosine A2A Inhibitor

Patient Disease:

Canine Lymphoma, Soft Tissue Sarcoma, Metastatic Osteosarcoma, or Hepatocellular Carcinoma

Study Name:

Preclinical Evaluation of a Novel Adenosine A2A Inhibitor in Dogs with Spontaneous Neoplasia

Purpose of the study:

  • Evaluate the safety and antitumor activity of a new drug given to dogs with certain types of cancer (lymphoma, soft-tissue sarcoma, osteosarcoma that has spread to the lungs, or hepatocellular carcinoma) that have not yet been treated or have failed other types of treatment

Primary Eligibility Criteria:

  • Dogs with confirmed lymphoma, soft-tissue sarcoma, metastatic osteosarcoma, or hepatocellular carcinoma

  • Weight at least 10 kg (22 lb)

  • Must have good function of liver and kidneys, and be free of severe underlying disease

  • Owners must be able to give oral medications twice daily

  • 2 week washout from chemotherapy, 6 weeks from radiation, 2 weeks from steroids

Study Protocol:

  • Determine eligibility: Physical examination, lab work, chest x-rays

  • Day 0: Physical exam, study blood collection, +/- CT scan (HCC & OSA), +/- tumor biopsy (LSA & STS), administer study drug

  • Week 1: Physical examination, lab work, study blood collection for 24 hours (overnight hospital stay may be necessary)

  • Weeks 2 & 3: Physical exam, lab work, study blood collection, tumor biopsy

  • Week 4: Physical exam, lab work, study blood collection, +/- CT scan (HCC & OSA), +/- tumor biopsy (LSA & STS)

  • Every 2 weeks: Physical exam, lab work, study blood collection; CT done every 6 weeks for HCC & OSA

Owner Responsibilities:

  • To make and keep all appointments for the study protocol

  • Administer oral medications at home

  • Complete daily log to document drug administration and side effects

Financial Incentives:

  • Study will cover all costs related to the study as well as the treatment of any side effects that occur due to the study drug + $1000 VTH credit at study completion

  • The owner is responsible for costs of tests needed to confirm study eligibility


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.